全文获取类型
收费全文 | 877篇 |
免费 | 55篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 60篇 |
妇产科学 | 39篇 |
基础医学 | 80篇 |
口腔科学 | 29篇 |
临床医学 | 97篇 |
内科学 | 209篇 |
皮肤病学 | 14篇 |
神经病学 | 92篇 |
特种医学 | 24篇 |
外科学 | 101篇 |
综合类 | 6篇 |
预防医学 | 86篇 |
眼科学 | 20篇 |
药学 | 30篇 |
肿瘤学 | 51篇 |
出版年
2023年 | 10篇 |
2022年 | 8篇 |
2021年 | 42篇 |
2020年 | 24篇 |
2019年 | 38篇 |
2018年 | 46篇 |
2017年 | 29篇 |
2016年 | 35篇 |
2015年 | 27篇 |
2014年 | 35篇 |
2013年 | 40篇 |
2012年 | 66篇 |
2011年 | 59篇 |
2010年 | 35篇 |
2009年 | 22篇 |
2008年 | 52篇 |
2007年 | 44篇 |
2006年 | 37篇 |
2005年 | 35篇 |
2004年 | 22篇 |
2003年 | 19篇 |
2002年 | 26篇 |
2001年 | 14篇 |
2000年 | 6篇 |
1999年 | 17篇 |
1998年 | 4篇 |
1996年 | 5篇 |
1995年 | 3篇 |
1992年 | 5篇 |
1991年 | 4篇 |
1990年 | 4篇 |
1989年 | 6篇 |
1988年 | 12篇 |
1987年 | 12篇 |
1986年 | 13篇 |
1985年 | 10篇 |
1984年 | 14篇 |
1983年 | 9篇 |
1982年 | 7篇 |
1980年 | 7篇 |
1978年 | 3篇 |
1977年 | 2篇 |
1976年 | 3篇 |
1973年 | 2篇 |
1972年 | 3篇 |
1971年 | 4篇 |
1970年 | 6篇 |
1969年 | 3篇 |
1967年 | 2篇 |
1966年 | 2篇 |
排序方式: 共有942条查询结果,搜索用时 31 毫秒
1.
2.
3.
4.
5.
6.
Neal J. Thomas Debbie Spear Emily Wasserman Steven Pon Barry Markovitz Aalok R. Singh Simon Li Shira J. Gertz Courtney M. Rowan Allen Kunselman Robert F. Tamburro 《Biology of blood and marrow transplantation》2018,24(12):2479-2486
To assess if calfactant reduces mortality among children with leukemia/lymphoma or after hematopoietic cell transplantation (HCT) with pediatric acute respiratory distress syndrome (PARDS), we conducted a multicenter, randomized, placebo-controlled, double-blinded trial in 17 pediatric intensive care units (PICUs) of tertiary care children's hospitals. Patients ages 18 months to 25 years with leukemia/lymphoma or having undergone HCT who required invasive mechanical ventilation for bilateral lung disease with an oxygenation index (OI) > 10 and <37 were studied. Interventions used were intratracheal instillation of either calfactant or air placebo (1 or 2 doses). Forty-three subjects were enrolled between November 2010 and June 2015: 26 assigned to calfactant and 17 to placebo. There were no significant differences in the primary outcome, which was survival to PICU discharge (adjusted hazard ratio of mortality for calfactant versus placebo, 1.78; 95% confidence interval, .53 to 6.05; P?=?.35), OI, functional outcomes, or ventilator-free days, adjusting for risk strata and Pediatric Risk of Mortality (PRISM) score. Despite the risk-stratified randomization, more allogeneic HCT patients received calfactant (76% and 39%, respectively) due to low recruitment at various sites. This imbalance is important because independent of treatment arm and while adjusting for PRISM score, those with allogeneic HCT had a nonsignificant higher likelihood of death at PICU discharge (adjusted odds ratio, 3.02; 95% confidence interval, .76 to 12.06; P?=?.12). Overall, 86% of the patients who survived to PICU discharge also were successfully discharged from the hospital. These data do not support the use of calfactant among this high mortality group of pediatric leukemia/lymphoma and/or HCT patients with PARDS to increase survival. In spite of poor enrollment, allogeneic HCT patients with PARDS appeared to be characterized by higher mortality than even other high-risk immunosuppressed groups. Conducting research among these children is challenging but necessary, because survival to PICU discharge usually results in successful discharge to home. 相似文献
7.
8.
Shira Doron Patricia L. Hibberd Barry Goldin Cheleste Thorpe Laura McDermott David R. Snydman 《Antimicrobial agents and chemotherapy》2015,59(8):4593-4599
Vancomycin-resistant enterococci (VRE) are endemic in health care settings. These organisms colonize the gastrointestinal tract and can lead to infection which is associated with increased mortality. There is no treatment for VRE colonization. We conducted a randomized, double-blind, placebo-controlled clinical trial to examine the safety and efficacy of administration of the probiotic Lactobacillus rhamnosus GG (LGG) for the reduction or elimination of intestinal colonization by VRE. Colonized adults were randomized to receive LGG or placebo for 14 days. Quantitative stool cultures for LGG and VRE were collected at baseline and days 7, 14, 21, 28, and 56. Day 14 stool samples from some subjects were analyzed by quantitative PCR (qPCR) for LGG. Patients were closely monitored for adverse events. Eleven subjects, of whom 5 received LGG and 6 received placebo, were analyzed. No differences in VRE colony counts were seen at any time points between groups. No decline in colony counts was seen over time in subjects who received LGG. LGG was detected by PCR in all samples tested from subjects who received LGG but was only isolated in culture from 2 of 5 subjects in the LGG group. No treatment-related adverse events were seen. We demonstrated that LGG could be administered safely to patients with comorbidities and is recoverable in some patients'' stool cultures. Concomitant administration of antibiotics may have resulted in an inability to recover viable organisms from stool samples, but LGG DNA could still be detected by qPCR. LGG administration did not affect VRE colonization in this study. (This study was registered at Clinicaltrials.gov under registration no. .) NCT00756262相似文献
9.
10.